European Institute for Molecular Imaging (EIMI) and Department of Nuclear Medicine of the University Hospital of Münster, Westfälische Wilhelms-Universität (WWU), Münster, Germany.
Eur J Nucl Med Mol Imaging. 2013 Oct;40(10):1595-606. doi: 10.1007/s00259-013-2464-1. Epub 2013 Jun 11.
Angiogenesis is a key event in the progression of glioblastomas (GBM). Our goal was to measure different anatomical and physiological parameters of GBM vessels using steady-state contrast-enhanced magnetic resonance imaging (SSCE-MRI), together with the assessment of biochemical parameters on GBM proliferation and angiogenesis using [(11)C]methyl-L-methionine (MET) and 3'-deoxy-3'-[(18)F]fluorothymidine (FLT) and positron emission tomography (PET). We focused on how these anatomical and biochemical read-outs correlate with one another and with immunohistochemistry.
SSCE-MRI together with (11)C-MET and (18)F-FLT PET were performed 3 weeks after intracranial implantation of human GBM spheroids in nude rats (n = 8). Total cerebral blood volume (tCBV), blood volume present in microvessels (μCBV), vessel density and size were calculated. Rats were treated with bevacizumab (n = 4) or vehicle (n = 4) for 3 weeks. Imaging was repeated at week 6, and thereafter immunohistochemistry was performed.
Three weeks after implantation, MRI showed an increase of vessel density and μCBV in the tumour compared to the contralateral brain. At week 6, non-treated rats showed a pronounced increase of (11)C-MET and (18)F-FLT tumour uptake. Between weeks 3 and 6, tCBV and vessel size increased, whereas vessel density and μCBV decreased. In rats treated with bevacizumab μCBV values were significantly smaller at week 6 than in non-treated rats, whereas the mean vessel size was higher. Accumulation of both radiotracers was lower for the treated versus the non-treated group. Most importantly, non-invasive measurement of tumour vessel characteristics and tumour proliferation correlated to immunohistochemistry findings.
Our study demonstrates that SSCE-MRI enables non-invasive assessment of the anatomy and physiology of the vasculature of experimental gliomas. Combined SSCE-MRI and (11)C-MET/(18)F-FLT PET for monitoring biochemical markers of angiogenesis and proliferation in addition to vessel anatomy could be useful to improve our understanding of therapy response of gliomas.
血管生成是胶质母细胞瘤(GBM)进展的关键事件。我们的目标是使用稳态对比增强磁共振成像(SSCE-MRI)测量 GBM 血管的不同解剖学和生理学参数,同时使用 [(11)C]甲基-L-蛋氨酸(MET)和 3'-去氧-3'-[(18)F]氟胸苷(FLT)和正电子发射断层扫描(PET)评估 GBM 增殖和血管生成的生化参数。我们专注于这些解剖学和生化读数如何相互关联以及与免疫组织化学相关。
在裸鼠颅内植入人 GBM 球体后 3 周,进行 SSCE-MRI 联合 [(11)C]MET 和 [(18)F]FLT PET(n = 8)。计算总脑血容量(tCBV)、微血管内血容量(μCBV)、血管密度和大小。将大鼠分为贝伐单抗治疗组(n = 4)和对照组(n = 4),治疗 3 周。在第 6 周时重复成像,然后进行免疫组织化学检查。
植入后 3 周,MRI 显示肿瘤的血管密度和 μCBV 与对侧大脑相比增加。在第 6 周时,未经治疗的大鼠显示出明显增加的 [(11)C]MET 和 [(18)F]FLT 肿瘤摄取。在第 3 周到第 6 周之间,tCBV 和血管大小增加,而血管密度和 μCBV 减少。在贝伐单抗治疗组中,第 6 周时 μCBV 值明显小于未经治疗的大鼠,而平均血管大小更高。与未经治疗的组相比,两种示踪剂的积累较低。最重要的是,肿瘤血管特征和肿瘤增殖的无创测量与免疫组织化学发现相关。
我们的研究表明,SSCE-MRI 能够无创评估实验性胶质瘤血管的解剖和生理学。结合 SSCE-MRI 和 [(11)C]MET/[(18)F]FLT PET 监测血管生成和增殖的生化标志物以及血管解剖学可能有助于提高我们对胶质瘤治疗反应的理解。